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specificity: 98.1%), the risk of failure is 9.8% (8/82) for patients 
not having received ADT. For patients who received ADT, the 
predictive factors of failure are PSA-60 (OR:53.9 p < 0.0001) and 
T-Stage (OR:0.25 p = 0.0008). Using this model and a PSA-60 cut-
off of 0.1 ng/mL (sensitivity: 85%, specificity: 92.9%), the 
predicted risk of BF in the rising PSA group is 53.7% (36/56). 
Taking into account the two predictive models, the anticipated 
cure rate for the entire cohort is 89.7%. 
Conclusions: Patients treated with LDR-PB monotherapy and 
whose PSA-60 is ≤ 0.3 ng/mL are highly likely to be cured even if 
they experienced a slight PSA rise. However, for patients who 
also received ADT, a stricter cut-off of 0.1 ng/mL may be 
appropriate. 
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Purpose:  The purpose of this study was to explore the cancer 
demographics in First Nations (FN) versus general population 
living in the remote island communities of Haida Gwaii, with 
similar access to cancer care services. 
Methods and Materials:  Medical charts of all 587 patients 
diagnosed with cancer from a period of 1970 until 2014 were 
retrieved from the British Columbia Cancer Agency registry and 
Northern Health database. Patients were categorized as FN or 
general population based on knowledge from community leader 
co-investigators. Estimates on breast cancer incidence in the 
period of 2001-2010 were calculated from the number of women 
in each community as per the Canadian Cancer Society census 
for that decade. Chi-square associations and multivariable Cox 
model was used to evaluate the association between FN versus 
non-FN status and mortality, after adjusting for clinical and 
treatment variables. 
Results:  A total of 587 patient charts were analyzed, with a 
median age at diagnosis of 62 years. Overall, 26% of cancer 
diagnoses were in patients of FN descent. Overall, 18% had 
confirmed smoking status, and 34% had a baseline performance 
status of 0-1. The most common cancer primary was genito-
urinary (GU: 17%), followed by gastro-intestinal (GI: 14%), breast 
(13%) and lung cancers (13%), while 14% were unknown. Stage I-
II presentation was seen in 21% and Stage III-IV was seen in 12% 
of the entire cohort. Surgery was performed in 26%, radiation 
therapy in 16% and chemotherapy was prescribed to 18%, but the 
status on cancer treatment was unknown in 54% of the cohort. 
The median number of trips made from the patient's hometown, 
up to and including initial treatment date was two (range, 1-5), 
with no difference between FN and non-FN group. Comparing FN 
versus non-FN population, significant clinical and treatment 
characteristics were: males (47% versus 58%; p = 0.03), breast 
cancer (23% versus 11%; p < 0.001), and GI cancers (22% versus 
13%; p < 0.001). There was no significant difference in overall 
survival (hazard ratio=1.28, 95% confidence interval: 0.77-2.16; 
p = 0.34).The estimated annual incidence for breast cancer in FN 
group was 2.2 cases per 1000, and 1.47 cases per 1000 for the 
non-FN population, while the Canadian estimate is 0.97 per 1000. 
Conclusions:  Breast cancer was more commonly seen in FN with 
an estimated 50% increased incidence of breast cancer as 
compared to the general population in Haida Gwaii, though the 
study sample size is small. The cancer care pathway and overall 
survival appear similar between the FN and non-FN cancer 
patients. 
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Purpose:  In the past decade, health care services for patients 
diagnosed with brain metastases have changed considerably with 
respect to decision-making, diagnostic sensitivity, systemic 
therapy options, surgical/radiosurgical approaches, and 
interdisciplinary management, including early palliative care 
support. Considering the combined effects of these changes, we 
hypothesized that, when compared to our institutional historical 
series of 2000-2005 (published 2011), survival has improved for 
those brain metastases patients seen between 2011-2015.  
Methods and Materials: From January 2011 to December 2015, 
patients with a new diagnosis of brain metastases referred to our 
regional cancer centre were triaged by a clinical nurse specialist, 
including after-hours referrals to the on-call radiation 
oncologists. Prophylactic cranial irradiation, hematological 
malignancies, non-Canadian, and cases without a consultation 
visit were excluded. Historical data from 2000-2005 was cleaned 
and updated; out-of-province cases lost to follow up were 
excluded. Survival time was measured from date of CT/MR 
diagnosis to date of death or censored at last contact. 
Proportional hazard regression model was pre-specified to test 
period effect (2011-15 versus 2000-05), adjusting for age and 
primary (lung, breast, melanoma, others). Prior to survival 
analysis, a clinically meaningful median survival gain was defined 
as one month or more for lung, breast and melanoma primaries. 
Results: From 2011-15, 688 cases were referred, of whom 675 
were included in this analysis (82% have died); from 2000-05, 555 
cases. Median age was 63 years and 61 years, respectively. The 
2011-15 cohort comprised of lung, breast, melanoma, and other 
cancers in 54%, 17%, 7.8% and 21% respectively; for 2000-05, 62%, 
13%, 4.5% and 21%. Median survival was 3.9 months for the 2011-
15 cohort (CL 3.4-4.2 months; 36% at 6 months) and 3.1 months 
for 2000-05 (CL 2.8-3.5 months; 30% at six months), Log rank p = 
0.0002 (lung 3.8 months versus 3.0 months; breast 3.8 months 
versus 4.0 months; melanoma 5.9 months versus 4.7 months). 
Adjusted for age, survival improvement was significant for lung 
(HR 0.78, CL 0.67-0.91), but not breast (HR 0.83, CL 0.61-1.1) 
nor melanoma (HR 0.76, CL 0.43-1.3). 
Conclusions: Even though the pre-defined magnitude of survival 
gain was not observed, the combined effects of advances in 
diagnosis, therapeutic strategies, and interdisciplinary 
collaboration on patients with brain metastases were associated 
with a modest improvement in survival outcome. While 
subgroups of patients might have benefited more from aggressive 
management, two out of three patients succumbed within six 
months of diagnosis. Palliative, supportive and transitional care 
services remain a clinical priority for the majority of brain 
metastases patients. 
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Purpose: To compare the combined intracavitary/interstitial 
brachytherapy (IC/IS) with intracavitary brachytherapy alone 
(IC) in cervical cancer treated with definitive radio-
chemotherapy and MRI guided adaptive brachytherapy (BT) 
within the EMBRACE study and the impact on target dose, OAR 
dose and late morbidity. 
Methods and Materials: The EMBRACE database containing 1129 
cervix cancer patients enrolled in the study with treatment 
completed before 09/2014 was used for this study. Patients 
having a MRI based parametrial infiltration status (PI) at time of 
BT (n = 999) were divided according to their PI status at first BT: 
no PI (456 patients), proximal PI (412 patients) and distal + pelvic 
wall PI (122 patients). Patients in each group were compared 
according to the use of IC or IC/IS during the course of their 
treatment, to dose in the HRCTV, OARs, and to late morbidity. 
T-test was performed on target and OAR doses (all EQD2 with 
α/β of 10 and 3 Gy) and Chi-square test was performed on 
patients’ characteristics variables. Univariate analysis of 
morbidity Grade 2 and more (G2≤) (rectum, bladder, bowel, 
vagina, overall morbidity) was performed with actuarial 
probabilities based on Kaplan-Meier statistics. 
Results: The median follow up was 23 and 26 months for the IC/IS 
and IC group, respectively. IC/IS patients with proximal PI had 
significantly less G2≥ bladder (19% versus 28%, p = 0.014), bowel 
(10% versus 22%, p = 0.002) and overall morbidity (51% versus 
68%, p = 0.003) at three years, but no difference in G2 ≥ rectal 
and vaginal morbidity. A significant dose decrease was found for 
bowel D2cm3 in the IC/IS group in comparison to the IC group (61 
± 8 Gy versus 63 ± 10Gy) while the same mean dose (D90) to the 
HRCTV was given. Rectal and bladder D2cm3 was not significantly 
different. Patients with distal or pelvic wall PI experienced less 
rectal (13% versus 46%, p = 0.001) and bowel (13% versus 40%, p 
= 0.054) morbidity G2≥ at three years in the IC/IS group in 
comparison to the IC group while bladder and vaginal toxicities 
were not significantly different. Patients in the IS/IC group 
received a significantly higher HR CTV D90 (87 ± 9 Gy versus 80 ± 
13 Gy, p < 0.001). 
Conclusions: These results demonstrate that regardless of the 
extent of PI, the dosimetric and clinical advantages of combined 
intracavitary/interstitial brachytherapy compared to 
intracavitary brachytherapy alone are substantial. IC/IS 
brachytherapy allows for a significantly higher HRCTV D90 (7Gy) 
in patients with distal and pelvic wall PI than IC brachytherapy 
while leading to less rectal and bowel morbidity. For patients 
with proximal PI, the use of IC/IS brachytherapy was associated 
with less bladder, bowel and overall morbidity while allowing for 
the same target dose. Potential biases induced by treatment 
related factors still have to be addressed in a multivariate 
analysis. A more systematic use of IC/IS brachytherapy in cervix 
cancer patients with PI is therefore recommended, especially for 
OAR sparing and for increase of dose to the HRCTV. 
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Purpose: To report on the five-year efficacy results of patients 
with localized high-risk prostate cancer treated with a 
concomitant hypofractionated IMRT boost (simultaneous 
integrated boost) along with adjuvant androgen deprivation 
therapy (ADT). 
Methods and Materials: From 2004-2010, a prospective Phase I-
II study was conducted in patients with any one or more of the 
following: T3 disease, PSA > 20 ng/mL, or Gleason score 8-10. A 
dose of 45 Gy in 25 fractions was delivered to the pelvic lymph 
nodes along with a concomitant IMRT boost of 22.5 Gy to the 
prostate, resulting in a total dose of 67.5 Gy in 25 fractions to 
the prostate over five weeks. Adjuvant ADT was to be delivered 
for two to three years. Biochemical failure was determined by 
the Phoenix definition. Univariate and multivariate analyses 
were performed to look for predictive factors. A post-treatment 
prostate biopsy was to be performed at five years to assess for 
pathologic local control. 
Results: Two hundred and thirty patients were treated and 
followed for the primary five year efficacy endpoint. Patients not 
lost to follow up have a minimum follow up of five years. Median 
age of patients was 72 years. Sixty-seven percent had GS 8-10, 
44% had PSA > 20 ng/mL, and 27% had T3 disease. The median 
duration of ADT was 30.4 months. 79% received at least 18 
months of ADT. The median PSA nadir was 0.02 ng/mL. 92% 
achieved a testosterone nadir of < 0.7 nmol/L. Five year 
probability of testosterone recovery (> 1.7 nmol/L) was 53.9%. 
Five year biochemical control rate was 83.7%. Five year overall 
survival was 93.7%. PSA nadir < 0.5 ng/mL independently 
predicted for higher biochemical control (HR 0.014; p < 0.0001), 
while a PSA nadir < 0.1 ng/mL independently predicted for longer 
overall survival (HR 0.129; p = 0.0024). Starting ADT in an 
adjuvant fashion (versus neoadjuvant) independently predicted 
for higher biochemical control (HR 0.419; p = 0.0116). ADT for ≤ 
12 months independently predicted for worse overall survival 
compared to ADT for > 24 months (HR 6.667; p = 0.014). Of the 
45 patients who underwent a five year prostate biopsy, five 
(11.1%) had a positive result showing malignant cells with no 
radiation effect. The biochemical control and overall survival of 
patients who had a post-treatment biopsy were not different 
from those without a biopsy. Five year actuarial incidence of 
Grade ≥ 3 GI and GU toxicities were 1.9% and 7.2%, respectively. 
Conclusions: A concomitant hypofractionated IMRT boost 
delivering 67.5 Gy in 25 fractions to the prostate over five weeks 
combined with elective pelvic nodal irradiation and adjuvant 
ADT resulted in favourable five year biochemical control and 
overall survival rates for patients with localized high-risk 
prostate cancer. Lower PSA nadir predicted for higher 
biochemical control and longer overall survival. ADT duration of 
≤ 12 months was associated with decreased overall survival. 
Pathologic local failure rate as assessed by five-year post-
treatment biopsy was low. 
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Purpose: Serum LDH level is incorporated in the stage 
classifications of lymphoma, melanoma, and seminoma. Recent 
series have also shown it to be prognostic for nasopharyngeal 
cancer. We evaluated the prognostic value of pre-radiotherapy 
(pre-RT) LDH in HPV-related (HPV+) and unrelated (HPV–) non-
metastatic oropharyngeal cancer (OPC). 
Methods and Materials: All newly diagnosed p16-confirmed HPV+ 
and HPV– OPC patients receiving IMRT +/- chemotherapy from 
2005-2013 were reviewed. Pre-RT LDH level was recorded as a 
binary variable [elevated (E) versus non-elevated (NE)]. Overall 
survival (OS) and relapse-free survival (RFS) were compared 
between LDH E versus NE by HPV status. Multivariable analyses 
(MVA) assessed the prognostic value of LDH on OS and RFS overall 
and in the subset with normal liver function (by AST/ALT/ALP). 
Recursive partitioning analysis (RPA) created prognostic groups 
in HPV+ OPC combining TNM and LDH. 
